Company Overview and News

0
JMT Auto Limited - Clarification - Financial Results

2018-08-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513691 JMTAUTOLTD

0
JMT Auto Limited - Outcome of Board Meeting

2018-08-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513691 JMTAUTOLTD

0
JMT Auto Limited - Financial Result Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513691 JMTAUTOLTD

4
Liberty House to complete Adhunik Metaliks acquisition in 2 months

2018-07-09 moneycontrol
Liberty House, part of the UK-based GFG Alliance, will look to complete the acquisition of Adhunik Metaliks within two months after securing a green signal from the latter’s creditors.
AMKD 517146 513691 UHBTY 532727 AMTEKAUTO AKLD USHAMART ABGSHIP 532682 JMTAUTOLTD ADHUNIK 500477 500570 MAHSEAMLES 520077 TATAMOTORS AKLS 500265 ASHOKLEY TTM

0
JMT Auto Limited - Clarification - Financial Results

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513691 JMTAUTOLTD

0
JMT Auto Limited - Financial Result Updates

2018-05-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513691 JMTAUTOLTD

3
ONGC, Canara Bank, Hudco, Midhani results

2018-05-29 thehindubusinessline
Alps Ind, Berger Paints, BF Utilities, Bharat Rasayan, Bharat Wire Ropes, Binani Ind, Bombay Rayon, Canara Bank, CG Power Industrial, Deepak Fert, Esab India, Hanung Toys, Hudco, Hindustan Aeronautics, JMT Auto, Mishra Dhatu Nigam, McLeod Russel, Munjal Showa, ONGC, Pricol, Punj Lloyd, Simplex Infrastructures, Stampede Capital, Suzlon, Tide Water, Tata Tele, Unitech and Vivemed Labs are among the firms that will declare Q4/FY18 results on Wednesday.
590021 513691 523838 MUNJALSHOW PUNJLLOYD SIMPLEXINF 531723 CNRYY 533106 532430 532693 532483 BHARATRAS OIL JMTAUTOLTD ESABINDIA BFUTILITIE 520043 STAMPEDE CANBK 500133

0
JMT Auto Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
513691 JMTAUTOLTD

Related Articles

REPH: Recro Pharma Analysis and Research Report

15h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

15h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

16h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...